ESOZIM-20

Indications

• Chronic pain management
• Gastroesophageal reflux disease (GERD)
• Ulcerative colitis
• Crohn's disease
• Certain psychiatric disorders
• Chronic respiratory diseases

Dosage

Children: Refer to specific product information for pediatric dosing guidelines, as they vary based on the active ingredient and intended use.

Adults: Refer to specific product information for dosing guidelines, as they vary based on the active ingredient and intended use.

Mechanism of action

The delayed release mechanism typically involves the use of coatings or matrix systems that protect the active ingredient from immediate dissolution in the stomach. These formulations are often designed to dissolve in the more alkaline environment of the intestines, allowing for targeted delivery and absorption. This can enhance the bioavailability of certain medications that are unstable in acidic conditions or that require a specific site of absorption.

Pharmacodynamics

The pharmacodynamics of delayed release drugs depend on the active ingredient and its therapeutic class. Generally, these formulations allow for a sustained therapeutic effect and can lead to a more stable plasma concentration of the drug over time. This can be particularly beneficial for medications with a narrow therapeutic index or for chronic conditions that require consistent drug levels.

Pharmacokinetics

Pharmacokinetics of delayed release formulations vary based on the drug, its formulation, and the intended site of release. Typically, these drugs exhibit altered absorption profiles compared to immediate release forms. The onset of action may be delayed due to the time taken for the drug to reach the intestines. The peak plasma concentration and overall bioavailability may also be affected, often requiring careful monitoring and adjustment of dosing regimens.

Pregnancy

Use in pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult a healthcare provider.

Breast-feeding

Consult healthcare provider as the drug may pass into breast milk.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Gastroesophageal reflux disease (GERD)
• Erosive esophagitis
• Peptic ulcers
• Helicobacter pylori eradication
• Zollinger-Ellison syndrome

Dosage

Adults: The usual oral dose

Mechanism of action

Esomeprazole exerts its stomach acid-suppressing effects by covalently binding to cysteine residues on the H+/K+-ATPase enzyme at the secretory surface of gastric parietal cells. This action inhibits both basal and stimulated gastric acid secretion irreversibly, requiring the synthesis of new enzyme to restore acid production. By blocking the final step of gastric acid production, esomeprazole reduces gastric acidity in a dose-dependent manner.

Pharmacodynamics

Esomeprazole is a substituted benzimidazole that inhibits gastric acid secretion without exhibiting anticholinergic or H2 receptor antagonistic properties. It is indicated for the treatment of GERD, healing of erosive esophagitis, and eradication of H. pylori to reduce duodenal ulcer recurrence. The suppression of gastric acid secretion is dose-related and effective against various stimuli that promote acid secretion.

Pharmacokinetics

Esomeprazole is rapidly absorbed after oral administration, with peak plasma concentrations typically occurring within 1-2 hours. It undergoes extensive hepatic metabolism primarily by the cytochrome P450 system, especially CYP2C19, resulting in several metabolites. The elimination half-life is approximately 1-2 hours, though its antisecretory effects last longer. It is excreted predominantly in the urine. Dose adjustments may be necessary in patients with hepatic impairment.

Contra-indications

• Hypersensitivity to esomeprazole or any of its components
• Concomitant use with rilpivirine-containing products

Adverse effects

• Abdominal pain
• Constipation
• Diarrhea
• Dizziness
• Dry mouth
• Headache
• Insomnia
• Nausea
• Skin reactions
• Vomiting
• Bone fractures
• Confusion
• Depression
• Drowsiness
• Leucopenia
• Malaise
• Myalgia
• Paraesthesia
• Peripheral edema
• Thrombocytopenia
• Vertigo
• Vision disorders
• Agranulocytosis
• Alopecia
• Gynaecomastia
• Hallucination
• Hepatic disorders
• Hyperhidrosis
• Hyponatraemia
• Nephritis
• Tubulointerstitial nephritis
• Pancytopenia
• Photosensitivity reaction
• Severe cutaneous adverse reactions (SCARs)
• Stomatitis
• Taste altered
• Hypomagnesaemia

Interactions

• Esomeprazole may increase the exposure to cannabidiol
• Esomeprazole may increase the exposure to cilostazol

Precautions

• Increased risk of fractures, particularly in the elderly and when used at high doses for over a year
• Caution in patients at risk of osteoporosis; adequate intake of calcium and vitamin D is recommended
• May increase the risk of gastrointestinal infections, including Clostridioides difficile
• Symptoms of gastric cancer should be ruled out before treatment
• Use with caution in patients with hepatic impairment

Pregnancy

Use with caution. The manufacturer advises avoiding use unless necessary since the effects on the fetus are not fully known.

Breast-feeding

Manufacturer advises avoiding use as esomeprazole is present in breast milk and may cause diarrhea in nursing infants. However, amounts are probably too small to be harmful.

Storage

Store in a cool, dry place below 25°C. Keep out of

Mechanism of action

Esomeprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme at the secretory surface of gastric parietal cells. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. As the binding of esomeprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, esomeprazole's duration of antisecretory effect that persists longer than 24 hours. Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. The S- and R-isomers of omeprazole are protonated and converted in the acidic compartment of the parietal cell forming the active inhibitor, the achiral sulphenamide. By acting specifically on the proton pump, esomeprazole blocks the final step in acid production, thus reducing gastric acidity. This effect is dose-related up to a daily dose of 20 to 40 mg and leads to inhibition of gastric acid secretion.

Pharmacodynamics

Esomeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and <i>H. pylori</i> eradication to reduce the risk of duodenal ulcer recurrence. Esomeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H⁺/K⁺ ATPase at the secretory surface of the gastric parietal cell. By doing so, it inhibits acid secretion into the gsatric lumen. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. Esomeprazole is the s-isomer of [DB00338], which is a racemate of the S- and R-enantiomer. Esomeprazole has been shown to inhibit acid secretion to a similar extent as [DB00338], without any significant differences between the two compounds _in vitro_. PPIs such as esomeprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes. Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as esomeprazole has been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal _C. difficile_), reduced absorption of micronutrients including iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.